Non-small cell lung cancer Landscape

Most common type of lung cancer (~85% of cases). Includes adenocarcinoma, squamous cell, and large cell subtypes.

Drug	Company	Mechanism	Modality	Route	Stage
Teliso-V	ABBV	c-Met-targeting ADC	ADC	IV	FILED
Divarasib	ROG.SW	KRAS G12C Inhibitor	KRAS G12C inhibitor	Oral	PHASE3
Patritumab deruxtecan	DSNKY, AZN	HER3-directed (DXd payload)	ADC	IV	PHASE3
Orpathys	AZN	MET inhibitor	Small molecule	ORAL	PHASE3
V940	MRK	mRNA neoantigen vaccine	mRNA	IM	PHASE3
rilvegostomig	AZN	PD-1 + TIGIT dual blockade	Bispecific	IV	PHASE3
Imfinzi	AZN	PD-L1 inhibitor	Antibody	IV	APPROVED
Datroway	AZN, DSNKY	TROP2-directed (DXd payload)	ADC	IV	APPROVED
Tagrisso	AZN	EGFR TKI	Small molecule	ORAL	APPROVED
Enhertu	AZN, DSNKY	HER2-directed (DXd payload)	ADC	IV	APPROVED
Tafinlar + Mekinist	NVS	BRAF + MEK inhibitor combination	Small molecule	Oral	APPROVED
Tecentriq	ROG.SW	PD-L1 inhibitor	Antibody	IV	APPROVED
Avastin	ROG.SW	VEGF antagonist	Antibody	IV	APPROVED
Imjudo	AZN	CTLA-4 inhibitor	Antibody	IV	APPROVED
Keytruda	MRK	PD-1 inhibitor	Antibody	IV	APPROVED
Alunbrig	—	ALK inhibitor	Small molecule	PO	APPROVED
Rybrevant	GMAB	EGFRxMET bispecific	Bispecific	IV/SC	APPROVED
BLINCYTO	AMGN	CD19/CD3 BiTE (bispecific T-cell engager)	Bispecific T-cell engager (BiTE)	IV	APPROVED
LUMAKRAS	AMGN	KRAS G12C inhibitor	Small molecule	Oral	APPROVED
Libtayo	REGN	PD-1 inhibitor	Monoclonal antibody	IV	APPROVED
Bizengri	GMAB	Anti-HER2/HER3 bispecific (NRG1 fusion blocker)	Bispecific antibody	IV	APPROVED

KRAS G12C-mutated NSCLC, previously treated

NSCLC KRAS G12C Mutated

Non-Small Cell Lung Cancer

NRG1 fusion-positive NSCLC

EGFR exon 20 insertion NSCLC

Tecentriq APPROVEDAvastin APPROVED

NSCLC 1L (PD-L1 ≥50%, no EGFR/ALK)

Non-small cell lung cancer (adjuvant, EGFR-mutated)

HER2-positive non-small cell lung cancer

Unresectable non-small cell lung cancer

Resectable non-small cell lung cancer

Metastatic non-small cell lung cancer

NSCLC (EGFR-mutated, datopotamab)

Non-small cell lung cancer (EGFR-mutated)

EGFR-mutant non-small cell lung cancer

First-line non-small cell lung cancer

HER2-mutant non-small cell lung cancer

B-cell precursor ALL, Ph-negative, MRD-positive

Imfinzi + Imjudo - Locoregional HCC - Ph3 - ToplineCLINICAL

Imfinzi ± Imjudo - MIBC - Ph3 - ToplineCLINICAL

Tagrisso + Orpathys - EGFRm NSCLC - Ph3 - ToplineCLINICAL

Rybrevant - NSCLC - SC Formulation DataCLINICAL

Teliso-V - NSCLC - Accelerated ApprovalREGULATORY

Datroway + Imfinzi - NSCLC - Ph3 - Topline (TROPION-Lung08)CLINICAL

Datroway - TROP2 Biomarker-Directed - Ph3 - Start (TROPION-Lung17)CLINICAL

Enhertu + Pertuzumab - 1L HER2+ mBC - FDA Approval (DESTINY-Breast09)REGULATORY

Datroway - 1L mTNBC (PD-L1 neg) - FDA ApprovalREGULATORY

Sac-TMT + Keytruda - 1L NSCLC - Ph3 - Update (OptiTROP-Lung05)CLINICAL